Companies: Embil Pharmaceutical Co. Ltd.

Latest: Watch here for details of new products and services.

Our Products: Overview; Partnering Search; Company Profiling; Partneringtools; Reports; Partnering Consulting; Comparison
Forums: Visit our forums
Jobs: Visit our job site
Case Studies: See what others think about our service
Newsletter: Partnering update; Key reports; Subscribe
Quick Links: Profile now; Register now; Profiled companies; Featured events; Industry news; PR Newswire New!
Contact us: Send an email; Call us: +44 1904 520460; Request a callback
RSS Feeds: Keep up to date

Pharmalicensing Ltd
is a division of

Companies
Company details

Embil Pharmaceutical Co. Ltd.

Pharmaceutical Formulation development, Manufacturing and Distribution

Profile

Since 1945, Embil has been developing unique formulations for the Pharmaceutical Industry. Embil is ISO 9001(2000) certified by BVQI.

In 1994, one product, Neo-Penotran®, a wide spectrum antimicrobial-antiprotozoal-antifungal combination, was formulated as a vaginal pessary and cream, specially for the treatment of all three common types of vaginitis, namely candidal, bacterial and trichomonal vaginitis.This product has been extremely successful in every anti- vaginitis market it has been introduced into.

In 2006, two new versions of Neo-Penotran have been launched in Turkey. Neo-Penotran Forte is a once daily version and Neo-Penotran Forte-L contains lidocaine for immediate pain relief after application. The Neo-Penotran family of products have been licensed out to different companies including Bayer-Schering subsidiaries operating in various countries in Europe, Asia and Latin America.

In recent years, Embil's focus has been directed towards topical products for the treatment of acne and local pain management.

Formulation development emphasis has been on Polymeric Delivery Systems for controlled release of topical actives and the newly developed Lamellar Penetration System® (LPS) for fast skin permeation of molecules used in pain management.

A strong patent portfolio for Worldwide IP protection enables Embil and its marketing partners to invest in new products for the future.

Embil presently exports original pharmaceutical products to over 30 countries while new export territories are being are being added periodically.

Partnering strategy/interests

A strong product development pipeline is available for companies interested in co-development and co-marketing of new and unique products.

Out-licensing

Novel Dual Chamber Dispenser for Rx and OTC Dermatology Products

Novel Dual Chamber Dispenser with polycarbonate and stainless steel components for accurate Rx dosing. More

Kortos® Cream and Kortos® HC Cream For the treatment of acute hemorrhoids, anal fissure and anal pruritus.

Kortos® Cream contains anti-inflammatory-antipruritic-vasoconstrictor, astringent, antiseptic and local anesthetic in a special water repellant base. More

Neo-Penotran® topical broad spectrum anti-infective vaginal pessary and cream for the treatment of three main types of vaginal infections and mixed forms of vaginitis.

Each Dose of Neo-Penotran® contains a combination of Metronidazole and Miconazole Nitrate in therapeutic concentrations for the local treatment of the treatment three main types of vaginal infections and mixed forms of vaginitis. More

Sulidin® nimesulide LPS Non-Steroidal Topical Anti-inflammatory gel for the local treatment of painful inflammatory conditions.

Using a lamellar structure as a delivery system, the Sulidin® Nimesulide LPS gel provides enhanced percutaneous penetration of Nimesulide and reduced yellow staining on the skin. LPS Technology worldwide patents are pending. More

Press Releases

Sulidin® 1% Nimesulide LPS® gel receives European and US Patents

(17th Nov 2004) Sulidin® 1% LPS® Nimesulide gel receives European and US Patents for unique non-alcoholic soluble gel formulation More

New Clinical Study results on SULIDIN® 1% Nimesulide LPS gel presented at the 8'th World Congress on Clinical Pharamacology and Therapeutics, Brisbane, Australia, 1-6 August 2004.

(7th Nov 2004) New Clinical Study results on SULIDIN® 1% Nimesulide LPS gel presented at the 8'th World Congress on Clinical Pharamacology and Therapeutics, Brisbane, Australia, 1-6 August 2004. More

Two papers on Neo-Penotran® Forte and Neo-Penotran® Forte-L have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004

(29th Dec 2003) Two papers on Embil's novel triple-active topical products (Neo-Penotran® Forte and Neo-Penotran® Forte-L) have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004 More

Australian Patent Approval announced for SULIDIN LPS (Topical Nimesulide Gel) formulation.

(6th Jun 2003) Australian Patent Approval announced for SULIDIN LPS (Topical Nimesulide Gel) formulation. More

Recent Patent Approvals for SULIDIN® LPS® (Topical Nimesulide Gel)

(10th Oct 2002) Patents were recently granted in 12 new countries for SULIDIN® LPS® (Topical Nimesulide Gel). Licensees are sought in these and other territories worldwide. More

Two New Clinical study reports released for Kortos® HC Cream used in the treatment of benign anorectal diseases.

(9th Oct 2002) Two new studies on the Efficacy, Tolerability and Safety of Kortos® HC cream and Kortos® HC Suppository have been carried out, found to be highly efficacous and well tolerated with no clinically relevant systemic or local side/adverse effects More

Two new Clinical Study reports of Neo-Penotran® Forte to be presented at the 10'th ICID meeting in Singapore, 11-14 March 2002.

(18th Feb 2002) Two new Clinical Study reports of Neo-Penotran® Forte are to be presented at the 10'th International Congress on Infectious Diseases meeting to be held in Singapore between 11-14 March 2002. More

Sulidin® 1% Nimesulide LPS gel penetration data to be presented at 8'th PPP Conference

(8th Feb 2002) Rapid In-vitro Percutaneous Penetration Profile of Sulidin® 1% Nimesulide LPS topical gel to be presented at the 8'th International Conference on Percutaneous Penetration. More

TURKISH PATENT INSTITUTE ISSUES FIRST SULIDIN® (TOPICAL NIMESULIDE) PATENT: TR 2001 00455 B

(19th Nov 2001) Turkish patent office issues first Topical Nimesulide Patent for SULIDIN® under the title 'Nimesulide containing topical formulations'. More

Turkish Ministry of Health approves the sale of Sulidin® %1 Nimesulide Topical Gel

(25th Sep 2001) Sulidin® %1 Gel is the first patented topical product containing Nimesulide to be approved for the Turkish market. More

Head office

Embil Pharmaceutical Co. Ltd.
Eski Buyukdere Cad.
Tahiraga Cesme Sok. No: 11/1
Maslak
Istanbul
34398
Turkey

Tel: +90 2123283244
Fax: +90 2122777876
www | email

Contact details

Dr Koral Embil
VP
R/D

Company figures

Formed: 1945
Annual Turnover: $20,000,000 (2006)
Number of employees: 190

Related categories

Industry sector: Drug delivery / Rectal; Drug delivery / Topical; Drug delivery / Vaginal; Drug delivery / Otic / Liquid; Medical device / Therapeutic device; Medical device / Therapeutic device / Catheter; Pharmaceutical / Prescription; Pharmaceutical / OTC/Non-Prescription; Pharmaceutical / Generics
Therapeutic target: Cardiovascular / Cardiovascular disorder (other) / Hemorrhoidal; Central Nervous System; Central Nervous System / CNS (other); Central Nervous System / Pain / Pain, acute; Central Nervous System / Pain / Pain, neuropathic; Central Nervous System / CNS (other) / Peripheral neuropathy; Central Nervous System / Pain / Pain management general; Dermatological; Dermatological / Fungal infection; Dermatological / Pruritis; Dermatological / Skin infection (other); Dermatological / Dermatological (other); Dermatological / Dermatitis, atopic; Dermatological / Wound healing; Genito-urinary; Genito-urinary / Genito-urinary other / Reproductive health (other); Genito-urinary / Sexually transmitted diseases / Venereal disease (other); Genito-urinary / Gender related medicine female / Women's health (other); Genito-urinary / Gender related medicine female / Gynecological disorder (other); Infectious diseases; Infectious diseases / Diseases / Infection, fungal (other); Musculoskeletal / Muscular / Inflammation; Musculoskeletal / Skeletal / Arthritis (non-specific); Musculoskeletal / Skeletal / Rheumatic disorders (other); Other therapeutic; Other therapeutic / Other; Infectious diseases / Parasitic diseases; Infectious diseases / Parasitic diseases / Infection, parasitic

Industry news: Pharmalicensing provides comprehensive industry coverage.

Products:	Partnering Consulting	Partnering Search	Company Profiling	Comparision	Partneringtools	Reports
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Outsourcing
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search	Add your event
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic	Post your article
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Company releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us